Relief of inflammatory symptoms and pruritus in glucocorticoid-responsive dermatoses, such as psoriasis and atopic dermatitis. The liquid is indicated for use on the scalp.
Composition:
1 g Ointment, cream or liquid for skin use contains 1 mg mometasone furoate. The Ointment contains propylene glycol stearate; the liquid contains propylene glycol.
Action:
A topical preparation containing a glucocorticosteroid with a strong anti-inflammatory, anti-pruritic and vasoconstrictive effect. After topical administration, after an 8-hour contact of the preparation with the skin, approximately 0.7% mometasone furoate from the ointment and about 0.4% cream is absorbed into the bloodstream.
Contraindications:
Hypersensitivity to the active substance, other corticosteroids or any of the excipients. Common acne. Rosacea. Skin disappearance. Inflammation of the skin around the mouth. Bacterial infections (eg impetigo, purulent dermatitis), viral (eg herpes simplex, shingles and chickenpox, common warts, condylomata acuminata, infectious mollusc), parasitic and fungal skin (eg caused by dermatophytes or yeasts). Post-vaccination reactions. Skin tuberculosis. Syphilis skin lesions. Pruritus of the anus and genital area. Diaper dermatitis. Do not use damaged or ulcerated skin on the skin.
Precautions:
If symptoms of irritation or sensitization occur after applying the preparation, it should be discontinued and appropriate treatment should be given. If an infection occurs, appropriate antibacterial or antifungal treatment should be used. If no rapid and positive response to treatment occurs, the corticosteroid should be discontinued until the infections have been cured. Systemic absorption of topically administered corticosteroids may induce reversible suppression of the hypothalamic-pituitary-adrenal axis with potential deficiency of glucocorticosteroid after discontinuation. In some patients, systemic absorption of topical corticosteroids may also cause symptoms of Cushing's syndrome, hyperglycemia and glycosuria. Patients using a local corticosteroid on a large area of the skin or under an occlusive dressing should be subjected to periodic control for signs of suppression of the hypothalamic-pituitary-adrenal axis. All side effects reported with systemic corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children. In children, due to the greater than normal ratio of body surface area to weight, there is a higher probability of susceptibility to systemic toxicity when using equivalent doses of the drug. After prolonged and constant application on a large area of damaged skin, skin folds and under an occlusive dressing, local and systemic toxicity was found to be frequent. Occlusive dressings should not be used on children or on the face. If it is necessary to apply the preparation on the face, the treatment should last a maximum of 5 days. In all patients, regardless of age, long-term continuous therapy should be avoided. The drug should be used with caution in children aged 2 years or older, although the safety and efficacy of the medicine for more than 3 weeks has not been studied. It is not recommended in children under 2 years of age, as the safety and efficacy have not been established. age group. The lowest effective dose should be used to relieve the symptoms of the disease, especially in children. Chronic corticosteroid treatment may interfere with the growth and development of children. The topical preparation is not intended for ophthalmic treatment (including eyelid) due to the very rare risk of squamous glaucoma or subcapsular cataract. Particularly cautiously use in patients with psoriasis, because topical use of corticosteroids in psoriasis can be dangerous, includingdue to the recurrence of the disease caused by the development of tolerance, the risk of generalized pustular psoriasis and general toxic effects caused by disturbance of skin continuity. Glucocorticoids may alter the appearance of some lesions, which may make it difficult to make the right diagnosis, and may also delay the healing. Ointment and liquid - due to the content of propylene glycol, the preparation may cause skin irritation.
Pregnancy and lactation:
During pregnancy and lactation, treatment with the preparation should only be carried out on the advice of a physician. Avoid applying the drug to a large area of the body or for a longer period of time. There are no adequate data on the safety of the medicine in pregnant women. Local administration of corticosteroids to pregnant animals may cause fetal abnormalities, including cleft palate and intrauterine growth retardation. The likelihood of limiting fetal growth as a result of penetration of the glucocorticoid through the placenta barrier should be considered. The preparation should be used in pregnant women only if the potential benefits of the treatment justify the risk to the mother or the fetus. It should only be given to breastfeeding mothers after carefully considering the risk / benefit ratio of treatment. If higher doses or long-term therapy are indicated, breast-feeding should be discontinued.
Side effects:
Very rare: folliculitis, burning sensation, pruritus. Not known: infections, boils, paresthesias, contact dermatitis, dye deficiency, excessive hairiness, stretch marks, acne-like lesions, skin atrophy, pain at the site of use, reactions at the site of use. After the sudden discontinuation of a drug containing potent glucocorto-oids, a "rebound" effect may occur, manifesting as inflammation of the skin, increased redness, burning and stabbing pain.
Dosage:
Outwardly. Adults, adolescents and children> 2 years: once a day apply a thin layer of ointment, cream or a few drops of liquid on the affected skin (the liquid should be gently massaged until it is absorbed). If it is necessary to apply the drug to the face, the treatment should last a maximum of 5 days. Ointment is recommended for the treatment of dry, scaly and cracked lesions. The liquid is used on the scalp. After a sudden discontinuation of the drug, a "rebound" effect can occur - this can be prevented by gradually reducing the dose, eg before discontinuation of the drug should be treated intermittently.
(C)
